Download Supplementary Table 1 - Clinical Cancer Research

Supplementary Table 1. Individual data on the clinical response of lung cancers harboring E709K/A or G719A/S to gefitinib or erlotinib
ACC indicates the patients included in this study at the Aichi Cancer Center. G, gefitinib; E, erlotinib; RECIST, response evaluation
criteria in solid tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease;
Supplementary references
S1. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and
prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung
cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493-501.
S2. Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH, Hsu YC, et al. Frequent epidermal
growth factor receptor gene mutations in malignant pleural effusion of lung
adenocarcinoma. Eur Respir J. 2008;32:924-30.
S3. Tatematsu A, Shimizu J, Murakami Y, Horio Y, Nakamura S, Hida T, et al.
Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer
Res. 2008;14:6092-6.
S4. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine
kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of
unknown clinical significance in non-small cell lung cancer. Clin Cancer Res.
2011;17:3812-21.
S5. Fukihara J, Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, et al.
Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with
EGFR-mutant non-small cell lung cancer. Oncology. 2014;86:86-93.
S6. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, et al. First-line
gefitinib in patients with advanced non-small-cell lung cancer harboring somatic
EGFR mutations. J Clin Oncol. 2008;26:2442-9.
S7. Guan Y, Zhao H, Meng J, Yan X, Jiao S. Dramatic response to high-dose icotinib in
a lung adenocarcinoma patient after erlotinib failure. Lung Cancer. 2014;83:305-7.
S8. Hata A, Yoshioka H, Fujita S, Kunimasa K, Kaji R, Imai Y, et al. Complex mutations
in the epidermal growth factor receptor gene in non-small cell lung cancer. J Thorac
Oncol. 2010;5:1524-8.
S9. Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, et al. Primary resistance to
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients
with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an
exploratory study. Ann Oncol. 2013;24:2080-7.
S10. Umekawa K, Kimura T, Kudoh S, Suzumura T, Oka T, Nagata M, et al. Plasma
RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with
EGFR-TKIs. BMC research notes. 2013;6:139.
S11. Locatelli-Sanchez M, Couraud S, Arpin D, Riou R, Bringuier PP, Souquet PJ.
Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible:
exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
Lung. 2013;191:491-9.
S12. Keam B, Kim DW, Park JH, Lee JO, Kim TM, Lee SH, et al. Rare and complex
mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase
inhibitor in patients with non-small cell lung cancer. International journal of clinical
oncology. 2014;19:594-600.
S13. De Pas T, Toffalorio F, Manzotti M, Fumagalli C, Spitaleri G, Catania C, et al.
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with
non-small cell lung cancer harboring rare epidermal growth factor receptor
mutations. J Thorac Oncol. 2011;6:1895-901.
S14. Ichihara S, Toyooka S, Fujiwara Y, Hotta K, Shigematsu H, Tokumo M, et al. The
impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese
patients with non-small-cell lung cancer. Int J Cancer. 2007;120:1239-47.
S15. Takahashi R, Hirata H, Tachibana I, Shimosegawa E, Inoue A, Nagatomo I, et al.
Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib
treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin
Cancer Res. 2012;18:220-8.
S16. Cho SH, Park LC, Ji JH, Park S, Hwang DW, Lee JY, et al. Efficacy of EGFR
tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR
mutation. Cancer Chemother Pharmacol. 2012;70:315-20.
S17. Peng L, Song ZG, Jiao SC. Efficacy analysis of tyrosine kinase inhibitors on rare
non-small cell lung cancer patients harboring complex EGFR mutations. Scientific
reports. 2014;4:6104.
S18. Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA,
et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
J Thorac Oncol. 2013;8:45-51.
S19. Wu JY, Shih JY, Yang CH, Chen KY, Ho CC, Yu CJ, et al. Second-line treatments
after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer.
2010;126:247-55.
S20. Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, et al. Lung cancer with
epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib
treatment response. Clin Cancer Res. 2008;14:4877-82.
S21. Gottschling S, Herpel E, Eberhardt WE, Heigener DF, Fischer JR, Kohne CH, et al.
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from
molecular analyses of German long-term responders treated in the IRESSA
expanded access program (EAP). Lung Cancer. 2012;77:183-91.
S22. Nakajima T, Yasufuku K, Nakagawara A, Kimura H, Yoshino I. Multigene mutation
analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by
endobronchial ultrasound-guided transbronchial needle aspiration. Chest.
2011;140:1319-24.
S23. Janne PA, Borras AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, et al. A rapid
and sensitive enzymatic method for epidermal growth factor receptor mutation
screening. Clin Cancer Res. 2006;12:751-8.
S24. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor
heterogeneity of epidermal growth factor receptor mutations in lung cancer and its
correlation to the response to gefitinib. Cancer Sci. 2008;99:929-35.
S25. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, et al. Mutation in the
tyrosine kinase domain of epidermal growth factor receptor is a predictive and
prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Clin Cancer Res. 2005;11:3750-7.
S26. Chang JW, Hou MM, Hsieh JJ, Cheung YC, Wang HM, Chen JS, et al. Early
radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor
in non-small cell lung cancer patients with epidermal growth factor receptor
mutations: A prospective study. Biomedical journal. 2015;38:221-8.
S27. Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, et al.
'Classical' but not 'other' mutations of EGFR kinase domain are associated with
clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J
Cancer. 2007;97:1560-6.
S28. Hijiya N, Miyawaki M, Kawahara K, Akamine S, Tsuji K, Kadota J, et al.
Phosphorylation status of epidermal growth factor receptor is closely associated with
responsiveness to gefitinib in pulmonary adenocarcinoma. Hum Pathol.
2008;39:316-23.